Strong R&D Investments Drive Growth in the German Biotechnology Market Valued at $54.8 Billion in 2025

Germany biotechnology market was valued at $54.8 billion in 2025 and is projected to reach $100.7 billion by 2035, growing at a CAGR of 6.3% during the forecast period (2026–2035). The German biotechnology sector is characterized by a highly innovative cluster, a high level of public-private partnerships, and a well-functioning system of research institutes and competitive global biotechnology companies.  Through the European Medicines Agency (EMA), the Paul Ehrlich-Institut (PEI), and the BfArM (Federal Institute for Drugs and Medical Devices), Germany offers a regulatory framework for biotech innovations and promotes responsible biomedical safety, efficacy, and regulatory standards. Regulations that incentivise the adoption of innovative biotechnological processes, the development of alternative therapeutic ways consideration of more sustainable, biomanufacturing processes for health, agri-food, and industry, respectively.

Browse the full report description of “Germany Biotechnology Market Size, Share & Trends Analysis Report by Product (Instruments & Equipment, Reagents & Consumables, and Software & Services), by Technology (DNA Sequencing & Genomics, Cell Culture Technology, Nano biotechnology, Fermentation Technology, Chromatography & Separation, Tissue Engineering & Regenerative Medicine, CRISPR & Gene Editing, Proteomics & Protein Engineering, Bioinformatics, and Others) and by Application (Healthcare & Medical, Agriculture & Food, Industrial / Environmental and Marine Biotechnology), Forecast Period (2026-2035)” at https://www.omrglobal.com/industry-reports/germany-biotechnology-market

According to data published by BIO Deutschland in its 2024 report, German biotechnology companies continue to attract strong investor interest, with capital raised reaching €1.1 billion ($1.1 billion), representing a 17% increase compared to the previous year. Additionally, industry collaborations approached a near record level, with a potential total value of up to €11.4 billion ($12.3 billion). The sector’s innovative capacity also remains robust, as evidenced by the 169 ongoing clinical trials, marking a historic high for the German biotech industry.

German health care and consumer trends represent a bi-directional dynamic. Mature markets require newer innovative biologics - gene and cell therapies, precision medicine opportunities, which have established efficacy in clinical practice; communities at large are demanding more biotechnology that is consistent with sustainability, circular economy principles, and renewable bio-based solutions.

Key Market Players and Their Innovations

• German biotech companies like BioNTech SE, Evotec SE, CureVac N.V., MorphoSys AG, and Qiagen N.V. have competitive advantages based on their emphasis on innovative R&D, global partnerships with pharmaceutical companies, investments in next-generation innovative therapies, and sustainable bioprocessing.

• For instance, BioNTech SE is moving beyond the application of its mRNA platform technology to discover therapeutics for infectious diseases into oncology and rare diseases, utilizing AI-assisted discovery and targeted immunotherapies.

• In addition, Evotec SE spearheads innovation in its end-to-end drug discovery and development platforms using cell therapies, RNA medicines, and antibody-drug conjugates. Their sustainable manufacturing activities also demonstrate Germany's capabilities in green biotech and industrial applications.

Key Market Developments

• In April 2025, BioNTech SE reported on selected assets of its diversified pipeline in oncology, such as mRNA cancer immunotherapies, next generation immunomodulators, and targeted therapies, at the American Association for Cancer Research Annual Meeting in Chicago, Illinois. BioNTech presents preclinical data characterizing the mode of action of BNT327. BNT327 is an investigational next-generation bispecific antibody combining PD-L1 checkpoint inhibition with VEGF-A neutralization.

• In March 2023, Seamless Therapeutics announced a €11.8 million ($12.5 million) seed financing round, which will accelerate further development of its designer recombinases, a novel gene editing platform to transform the treatment of severe diseases. The company’s pioneering recombinase platform is able to program a widely used and established molecular biology tool to unlock the full potential of gene editing, enabling the targeting of any site within the genome.

Market Coverage

• The market number available for – 2025-2035
• Base year- 2025
• Forecast period- 2026-2035
• Segment Covered-
  • By Product
  • By Technology
  • By Application
• Competitive Landscape - Bayer AG, Merck KGaA, QIAGEN N.V., Novartis AG, and Boehringer Ingelheim International GmbH, among others.

Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Germany Biotechnology Market Report Segment

By Product

• Instruments & Equipment
• Reagents & Consumables
• Software & Services

By Technology

• DNA Sequencing & Genomics
• Cell Culture Technology
• Nano biotechnology
• Fermentation Technology
• Chromatography & Separation
• Tissue Engineering & Regenerative Medicine
• CRISPR & Gene Editing
• Proteomics & Protein Engineering
• Bioinformatics
• Others

By Application

• Healthcare & Medical
• Agriculture & Food
• Industrial / Environmental
• Marine Biotechnology

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/germany-biotechnology-market